Status:
COMPLETED
Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)
Lead Sponsor:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborating Sponsors:
Beijing Anzhen Hospital
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
We conduct this clinical trial to determine the effects of Xuefu Zhuyu capsule (based on TCM "Zheng Hou" theory) in helping recovery from coronary heart disease(CHD)after PCI and find out whether this...
Detailed Description
The effectiveness of a Chinese herbal formulae is not completely based on the disease or some biomedical indexes, but much more on the TCM syndrome(Chinese name:Zheng Hou)which is generalized from pat...
Eligibility Criteria
Inclusion
- 18-75 years old
- Clinical diagnosis of coronary heart disease (confirmed by coronary angiography)
- Successfully received interventional therapy (PTCA or PCI)
- belong to TCM blood-stasis syndrome
- Must be able to swallow tablets
- Able to give written informed consent
Exclusion
- Symptomatic congestive heart failure(New York Heart Association class III-IV)
- Females during pregnancy or lactation
- Serious dysfunction in important organs (liver, lung, kidney，et al)
- Use of concomitant Chinese herbal medicine
- Already attend other clinical trial
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00817024
Start Date
March 1 2008
End Date
March 1 2009
Last Update
June 1 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guang'an Men Hospital
Beijing, China, 100053